{"id":40514,"date":"2025-09-01T17:20:58","date_gmt":"2025-09-01T09:20:58","guid":{"rendered":"https:\/\/flcube.com\/?p=40514"},"modified":"2025-09-01T17:20:59","modified_gmt":"2025-09-01T09:20:59","slug":"sanofis-wayrilz-fda-approval-brings-new-oral-btk-inhibitor-for-itp","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40514","title":{"rendered":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP"},"content":{"rendered":"\n<p>The U.S. Food and Drug Administration (FDA) has granted approval to <strong>Sanofi\u2019s (NASDAQ: SNY) Wayrilz (rilzabrutinib)<\/strong> for the treatment of adult patients with persistent or chronic <strong>immune thrombocytopenia (ITP)<\/strong> who have not responded adequately to prior therapy. The decision is rooted in the pivotal <strong>Phase\u202f3 LUNA\u202f3<\/strong> study, which demonstrated that Wayrilz achieved both its primary and secondary endpoints, producing durable platelet count gains and meaningful relief of ITP symptoms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class, oral, reversible BTK inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Multi\u2011immune modulation<\/strong> \u2013 targets several pathways that drive platelet destruction<\/li>\n\n\n\n<li><strong>Rapid, sustained platelet response<\/strong> with a favorable safety profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h2>\n\n\n\n<p>Wayrilz selectively blocks Bruton&#8217;s tyrosine kinase (BTK), a pivotal enzyme in B\u2011cell receptor signaling. By interrupting BTK activity, the drug dampens autoreactive B\u2011cell and macrophage activity, thereby reducing platelet clearance. Its reversible binding allows for precise control of immune modulation, minimizing off\u2011target effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>FDA Approved<\/td><td>Adults with persistent or chronic ITP, inadequate response to prior therapy<\/td><\/tr><tr><td><strong>United Arab Emirates<\/strong><\/td><td>Approved<\/td><td>Adults with persistent or chronic ITP, inadequate response or intolerance to prior therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-directions\">Future Directions<\/h2>\n\n\n\n<p>Wayrilz is currently under investigation in several other rare immune\u2011mediated disorders where BTK inhibition may be therapeutic, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Warm autoimmune hemolytic anemia<\/li>\n\n\n\n<li>IgG4\u2011related disease<\/li>\n\n\n\n<li>Sickle cell disease<\/li>\n<\/ul>\n\n\n\n<p>These trials aim to extend the drug\u2019s impact beyond ITP, leveraging its broad immune\u2011modulatory profile.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi\u2019s (NASDAQ: SNY) Wayrilz&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40518,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[867,147],"class_list":["post-40514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40514\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP\" \/>\n<meta property=\"og:description\" content=\"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40514\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T09:20:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T09:20:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP\",\"datePublished\":\"2025-09-01T09:20:58+00:00\",\"dateModified\":\"2025-09-01T09:20:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0114.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40514#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40514\",\"name\":\"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0114.webp\",\"datePublished\":\"2025-09-01T09:20:58+00:00\",\"dateModified\":\"2025-09-01T09:20:59+00:00\",\"description\":\"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40514\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0114.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0114.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40514#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40514","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP","og_description":"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.","og_url":"https:\/\/flcube.com\/?p=40514","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-01T09:20:58+00:00","article_modified_time":"2025-09-01T09:20:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40514#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40514"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP","datePublished":"2025-09-01T09:20:58+00:00","dateModified":"2025-09-01T09:20:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40514"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40514#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","keywords":["NASDAQ: SNY","Sanofi"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40514#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40514","url":"https:\/\/flcube.com\/?p=40514","name":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40514#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40514#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","datePublished":"2025-09-01T09:20:58+00:00","dateModified":"2025-09-01T09:20:59+00:00","description":"The U.S. FDA has cleared Sanofi\u2019s Wayrilz (rilzabrutinib) for adults with chronic immune thrombocytopenia who failed prior therapy. The decision follows robust Phase\u20113 LUNA\u202f3 data and expands treatment options worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40514#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40514"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40514#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","width":1080,"height":608,"caption":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40514#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0114.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40514"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40514\/revisions"}],"predecessor-version":[{"id":40519,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40514\/revisions\/40519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40518"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}